Cartesian Therapeutics (RNAC) Operating Margin: 2015-2025
Historic Operating Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -4,660.62%.
- Cartesian Therapeutics' Operating Margin fell 11928.00% to -4,660.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -8,386.53%, marking a year-over-year decrease of 827493.00%. This contributed to the annual value of -112.81% for FY2024, which is 21951.00% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Operating Margin of -4,660.62% as of Q3 2025, which was up 36.32% from -7,319.13% recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Operating Margin peaked at 3,521.87% during Q4 2024, and registered a low of -7,319.13% during Q2 2025.
- Its 3-year average for Operating Margin is -1,498.20%, with a median of -355.08% in 2023.
- Its Operating Margin has fluctuated over the past 5 years, first tumbled by 798,160bps in 2021, then skyrocketed by 396,141bps in 2024.
- Over the past 5 years, Cartesian Therapeutics' Operating Margin (Quarterly) stood at 13.62% in 2021, then slumped by 6,421bps to -50.59% in 2022, then slumped by 38,895bps to -439.54% in 2023, then soared by 396,141bps to 3,521.87% in 2024, then tumbled by 11,928bps to -4,660.62% in 2025.
- Its last three reported values are -4,660.62% in Q3 2025, -7,319.13% for Q2 2025, and -1,989.91% during Q1 2025.